Posted by Michael Wonder on 08 Nov 2024
AskBio receives FDA rare paediatric disease and orphan drug designations for AB-1003 for the treatment of limb girdle muscular dystrophy type 2I/R9
7 November 2024 - First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with enrolment continuing
Asklepios BioPharmaceutical today announced that AB-1003 (also known as LION-101) has received rare paediatric disease designation and orphan drug designation from the US FDA for the treatment of limb-girdle muscular dystrophy type 2I/R9.
